Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $32.36, but opened at $31.33. Dyne Therapeutics shares last traded at $31.93, with a volume of 67,167 shares changing hands.

Wall Street Analysts Forecast Growth

DYN has been the subject of several recent research reports. Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $35.00 in a report on Thursday. Morgan Stanley lifted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Oppenheimer reissued an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $50.60.

Dyne Therapeutics Stock Performance

The firm has a fifty day simple moving average of $36.92 and a 200-day simple moving average of $34.66. The company has a market capitalization of $2.74 billion, a PE ratio of -8.15 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. This represents a -100.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. This represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 158,975 shares of company stock worth $5,693,789 over the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in Dyne Therapeutics by 25.5% in the fourth quarter. Wellington Management Group LLP now owns 145,474 shares of the company’s stock valued at $1,935,000 after buying an additional 29,539 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Dyne Therapeutics by 5.9% in the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after buying an additional 857 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 24.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock worth $812,000 after acquiring an additional 5,696 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $575,000. Finally, Jennison Associates LLC raised its holdings in shares of Dyne Therapeutics by 495.2% during the first quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after acquiring an additional 1,004,680 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.